Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Non-Current Assets (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Non-Current Assets data on record, last reported at $71.1 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 17.57% year-over-year to $71.1 million; the TTM value through Dec 2025 reached $308.7 million, down 15.34%, while the annual FY2025 figure was $71.1 million, 17.57% down from the prior year.
  • Non-Current Assets reached $71.1 million in Q4 2025 per TRDA's latest filing, down from $74.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $103.8 million in Q2 2023 and bottomed at $39.7 million in Q3 2022.
  • Average Non-Current Assets over 4 years is $74.2 million, with a median of $81.5 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: soared 156.71% in 2023, then dropped 17.57% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $42.2 million in 2022, then skyrocketed by 135.7% to $99.4 million in 2023, then fell by 13.22% to $86.3 million in 2024, then dropped by 17.57% to $71.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $71.1 million in Q4 2025, $74.6 million in Q3 2025, and $79.6 million in Q2 2025.